Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Articles|December 1, 2012

Doing what's right for you is the key for investing

The key to determining what to invest in should be based primarily on the needs, temperament, and available resources of each individual or family.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Jenny Guo, MD, discusses outcomes with hemi-HoLEP after pelvic radiation

ByJenny N. Guo, MD

June 16th 2026

Daniel Eun, MD, on telesurgery, AI, and the future of reconstructive urology

ByDaniel D. Eun, MD,Hannah Clarke

June 16th 2026

Louise Emmett, MD, PhD, highlights early data on 225Ac-PSMA-617 in mCRPC

ByLouise Emmett, MD, PhD, MBChB, FRACP

June 16th 2026

Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC

ByToni K. Choueiri, MD

June 15th 2026

ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer

ByHannah Clarke

June 15th 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Trending on Urology Times

Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC

Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring

FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC

The UroOnc Minute: Variant Histologies in Bladder Cancer, With Carissa Chu, MD

FDA approves adjuvant belzutifan with pembrolizumab for ccRCC